M. Martin Et Al. , "Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial," The Lancet Oncology , vol.18, no.12, pp.1688-1700, 2017
Martin, M. Et Al. 2017. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology , vol.18, no.12 , 1688-1700.
Martin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., ... von Minckwitz, G.(2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology , vol.18, no.12, 1688-1700.
Martin, Miguel Et Al. "Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial," The Lancet Oncology , vol.18, no.12, 1688-1700, 2017
Martin, Miguel Et Al. "Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet Oncology , vol.18, no.12, pp.1688-1700, 2017
Martin, M. Et Al. (2017) . "Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet Oncology , vol.18, no.12, pp.1688-1700.
@article{article, author={Miguel Martin Et Al. }, title={Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial}, journal={The Lancet Oncology}, year=2017, pages={1688-1700} }